Market Spotlight: Pancreatic Cancer
Market Spotlight: Pancreatic Cancer
€1,241.16
This Market Spotlight report covers the pancreatic cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the pancreatic cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were 453,200 incident cases of pancreatic cancer worldwide, and expects that number to increase to 495,900 incident cases by 2026.
- The approved drugs in the pancreatic cancer space target microtubules (tubulin), DNA, DNA synthesis, topoisomerase I, dihydropyrimidine dehydrogenase, thymidylate synthase, and epidermal growth factor receptor. These drugs are commonly administered via the intravenous route, with a few select products being available in oral and intratumoral formulations.
- The majority of industry-sponsored drugs in active clinical development for pancreatic cancer are in Phase II, with only one drug in the NDA/BLA phase.
- Therapies in development for pancreatic cancer focus on a wide variety of targets. The majority of pipeline drugs for pancreatic cancer are administered via the oral and intravenous routes.
- High-impact upcoming events for drugs in the pancreatic cancer space comprise topline Phase IIb and Phase III trial results, an expected PDUFA date for an sNDA, estimated CHMP supplemental filing results, and expected patent expirations.
The overall likelihood of approval of a Phase I pancreatic cancer asset is 1.9%, and the average probability a drug advances from Phase III is 12%. Drugs, on average, take 10.6 years from Phase I to approval, compared to 9.3 years in the overall oncology space. - There have been 50 licensing and asset acquisition deals involving pancreatic cancer drugs during 2014–19. The $1,770m exclusive clinical collaboration agreement signed in 2014 between Bristol-Myers Squibb and Five Prime Therapeutics to explore the combination of Opdivo with FPA008 in six tumor types including pancreatic cancer was the largest deal.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for pancreatic cancer have been in the early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
- The US has a substantial lead in the number of pancreatic cancer clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the pancreatic cancer space is dominated by completed trials. Roche has the highest number of completed clinical trials for pancreatic cancer, with 95 trials.
- Roche leads industry sponsors with the highest number of clinical trials for pancreatic cancer, followed by Pfizer and Eli Lilly.
CONTENTS
7 OVERVIEW
8 KEY TAKEAWAYS
9 DISEASE BACKGROUND
9 Subtypes
11 TREATMENT
11 Surgery
11 Ablation or embolization
12 Radiation therapy
12 Chemotherapy
12 Targeted therapy
13 Immunotherapy
13 Drugs used specifically for the treatment of PNETs
14 EPIDEMIOLOGY
17 MARKETED DRUGS
20 PIPELINE DRUGS
36 RECENT EVENTS AND ANALYST OPINION
36 Pegilodecakin for Pancreatic Cancer (October 16, 2019)
37 Acelarin for Pancreatic Cancer (August 20, 2019)
38 Mavorixafor for Pancreatic Cancer (July 17, 2019)
39 Napabucasin for Pancreatic Cancer (July 1, 2019)
40 Abraxane for Pancreatic Cancer (June 2, 2019)
41 Lynparza for Pancreatic Cancer (June 2, 2019)
43 NanoKnife System for Pancreatic Cancer (May 13, 2019)
44 MVT-5873 for Pancreatic Cancer (May 8, 2019)
45 Sacituzumab Govitecan for Pancreatic Cancer (April 29, 2019)
46 RX-3117 for Pancreatic Cancer (April 16, 2019)
47 Abraxane for Pancreatic Cancer (March 12, 2019)
49 Abraxane for Pancreatic Cancer (February 27, 2019)
50 BRACAnalysis Companion Diagnostic for Pancreatic Cancer (February 26, 2019)
51 Lynparza for Pancreatic Cancer (February 26, 2019)
52 SM-88 for Pancreatic Cancer (January 18, 2019)
54 Xuriden for Pancreatic Cancer (November 20, 2018)
56 BL-8040 for Pancreatic Cancer (October 19, 2018)
58 SpaceOAR System for Pancreatic Cancer (September 6, 2018)
59 IT-139 Companion Diagnostic for Pancreatic Cancer (June 25, 2018)
61 Pegilodecakin for Pancreatic Cancer (June 3, 2018)
63 RenovoCath (Catheter) for Pancreatic Cancer (May 23, 2018)
67 KEY UPCOMING EVENTS
68 PROBABILITY OF SUCCESS
69 LICENSING AND ASSET ACQUISITION DEALS
69 Novartis Snaps Up KRAS Inhibitor R&D
70 Deals Shaping The Medical Industry, October 2019
70 Spherix Gets Cancer IP From Kentucky, Maryland-Baltimore Universities
70 Tonix Signs Second License This Year With Columbia
70 Boehringer Ingelheim Snaps Up Lupin’s MEK Inhibitor For Difficult-To-Treat Cancers
71 Deals Shaping The Medical Industry, August 2019
71 Ono Licenses Rafael’s Novel Chemo-Sensitizing Agent For Asia
72 Mateon, Oncotelic Merge With Focus On Brain, Pancreatic Cancer Candidate
72 BioSense Picks Up Greater China Rights To Rexahn’s Cancer Candidate
73 PARENT PATENTS
75 REVENUE OPPORTUNITY
76 CLINICAL TRIAL LANDSCAPE
77 Sponsors by status
78 Sponsors by phase
79 Recent events
81 BIBLIOGRAPHY
81 Prescription information
83 APPENDIX
LIST OF FIGURES
16 Figure 1: Trends in incident cases of pancreatic cancer, 2017–26
20 Figure 2: Overview of pipeline drugs for pancreatic cancer in the US
20 Figure 3: Pipeline drugs for pancreatic cancer, by company
21 Figure 4: Pipeline drugs for pancreatic cancer, by drug type
21 Figure 5: Pipeline drugs for pancreatic cancer, by classification
37 Figure 6: Pegilodecakin for Pancreatic Cancer (October 16, 2019): Phase III – SEQUOIA (w/FOLFOX)
43 Figure 7: Lynparza for Pancreatic Cancer (June 2, 2019): Phase III – POLO
49 Figure 8: Abraxane for Pancreatic Cancer (March 12, 2019): Phase III – APACT – w/Gemcitabine (Adjuvant)
52 Figure 9: Lynparza for Pancreatic Cancer (February 26, 2019): Phase III – POLO
54 Figure 10: SM-88 for Pancreatic Cancer (January 18, 2019): Phase II – Tyme-88-Panc (>1L)
58 Figure 11: BL-8040 for Pancreatic Cancer (October 19, 2018): Phase IIa – COMBAT/KEYNOTE-202 (w/Keytruda)
63 Figure 12: Pegilodecakin for Pancreatic Cancer (June 3, 2018): Phase I/Ib – IVY
67 Figure 13: Key upcoming events in pancreatic cancer
68 Figure 14: Probability of success in the pancreatic cancer pipeline
69 Figure 15: Licensing and asset acquisition deals in pancreatic cancer, 2014–19
73 Figure 16: Parent patents in pancreatic cancer, 2019–25
74 Figure 17: Parent patents in pancreatic cancer, 2025–29
74 Figure 18: Parent patents in pancreatic cancer, 2029–38
76 Figure 19: Clinical trials in pancreatic cancer
76 Figure 20: Top 10 drugs for clinical trials in pancreatic cancer
77 Figure 21: Top 10 companies for clinical trials in pancreatic cancer
77 Figure 22: Trial locations in pancreatic cancer
78 Figure 23: Pancreatic cancer trials status
79 Figure 24: Pancreatic cancer trials sponsors, by phase
LIST OF TABLES
15 Table 1: Incident cases of pancreatic cancer, 2017–26
18 Table 2: Marketed drugs for pancreatic cancer
22 Table 3: Pipeline drugs for pancreatic cancer in the US
36 Table 4: Pegilodecakin for Pancreatic Cancer (October 16, 2019)
38 Table 5: Acelarin for Pancreatic Cancer (August 20, 2019)
39 Table 6: Mavorixafor for Pancreatic Cancer (July 17, 2019)
40 Table 7: Napabucasin for Pancreatic Cancer (July 1, 2019)
41 Table 8: Abraxane for Pancreatic Cancer (June 2, 2019)
42 Table 9: Lynparza for Pancreatic Cancer (June 2, 2019)
44 Table 10: NanoKnife System for Pancreatic Cancer (May 13, 2019)
45 Table 11: MVT-5873 for Pancreatic Cancer (May 8, 2019)
46 Table 12: Sacituzumab Govitecan for Pancreatic Cancer (April 29, 2019)
47 Table 13: RX-3117 for Pancreatic Cancer (April 16, 2019)
48 Table 14: Abraxane for Pancreatic Cancer (March 12, 2019)
49 Table 15: Abraxane for Pancreatic Cancer (February 27, 2019)
50 Table 16: BRACAnalysis Companion Diagnostic for Pancreatic Cancer (February 26, 2019)
51 Table 17: Lynparza for Pancreatic Cancer (February 26, 2019)
53 Table 18: SM-88 for Pancreatic Cancer (January 18, 2019)
55 Table 19: Xuriden for Pancreatic Cancer (November 20, 2018)
57 Table 20: BL-8040 for Pancreatic Cancer (October 19, 2018)
58 Table 21: SpaceOAR System for Pancreatic Cancer (September 6, 2018)
60 Table 22: IT-139 Companion Diagnostic for Pancreatic Cancer (June 25, 2018)
62 Table 23: Pegilodecakin for Pancreatic Cancer (June 3, 2018)
64 Table 24: RenovoCath (Catheter) for Pancreatic Cancer (May 23, 2018)
75 Table 25: Historical global sales, by drug ($m), 2014–18
75 Table 26: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the